Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

N-AD: A Randomized, Double Blind, Parallel Group, Placebo Controlled, Phase 2 Trial of Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease

NCT07741071 is registered in ClinicalTrials.gov with Haukeland University Hospital as lead sponsor.

NCT NCT07741071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07741071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
N-AD: A Randomized, Double Blind, Parallel Group, Placebo Controlled, Phase 2 Trial of Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease
Lead sponsor
Haukeland University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
August 26, 2026
Completion date
April 30, 2030
Enrollment
270 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease (ad)